Saxenda 6mg

Description

Saxenda is indicated as an adjunct to a hypocaloric diet and increased physical activity for weight control in adult patients with an initial Body Mass Index (BMI):

• ≥ 30 kg/m2 ⁽ obesity), or
• ≥ 27 kg/m ² and < 30 kg/m ² (overweight) in the presence of at least one weight-related comorbidity factor such as dysglycemia (prediabetes or type 2 diabetes), high blood pressure, dyslipidemia or obstructive sleep apnea syndrome.

Treatment with Saxenda should be discontinued after 12 weeks at a dose of 3.0 mg/day if patients have not lost at least 5% of their initial body weight.
Adolescents (≥ 12 years):
Saxenda can be used as an adjunct to a healthy diet and increased physical activity for weight control in adolescent patients from 12 years of age who have:

• obesity (corresponding to a BMI ≥ 30 kg/m ² in adults according to international thresholds)* and
• a body weight greater than 60 kg.

Saxenda treatment should be discontinued and reassessed if patients have not lost at least 4% of their BMI or BMI Z-score after 12 weeks at 3.0 mg/day or the maximum tolerated dose.
*IOTF BMI cut-offs for obesity by gender between 12 and 18 years (see Table 1):